SPI-077 is essentially inactive against SCCHN and, in its present formulation, does not merit further evaluation as induction chemotherapy or as part of a CCRT approach.

Future studies may support our hypothesis that the pretreatment serum level of MMP-9 is a new powerful prognostic marker and can help to stratify NSCLC patients with stage I/II disease into low- and high-risk groups.

Objectives To design and establish a model to examine in left renal tissue integrity on day 2 only (P<0.001), whereas RI for 40 min caused significant left renal whether brief periods of renal artery occlusion (ischaemic preconditioning, IP) confers protection dysfunction on day 0, day 2 and day 9 (P∏0.01). For a given duration of ischaemia, there was no significant from the eÂects of a subsequent period of ischaemia and reperfusion of the rat kidney.diÂerence between results from (IP+RI) rats compared with RI-only rats at any of the three times. There was Materials and methods Ninety rats were randomized into six groups, i.e. sham-operated controls; IP alone; no significant alteration in renal tissue integrity in the IP-only rats compared with sham-operated controls. a 20 or 40 min period of left renal ischaemia (RI) alone; and IP followed by a 20 or 40 min period of Histological findings paralleled the data obtained from DMSA uptake. RI. Preconditioning involved the sequential clamping of the left renal artery for 4 min and its release for 11Conclusions The IP regimen and 30 min 'critical interval' confers no protection to the kidney from a 20 or min, a total of four times, a 'critical interval' of 30 min before the ischaemic insult. Left renal tissue integrity 40 min ischaemic episode. The IP regimen itself appears to have no eÂect, confirming the validity of was determined by dimercapto-succinic acid (DMSA) radionuclide imaging on a c-camera both immediately our experimental model.

This article reviews available radionuclide-based techniques for glomerular filtration rate (GFR) measurement, focusing on clinical indications for GFR measurement, ideal GFR radiopharmaceutical tracer properties, and the 2 most common tracers in clinical use. Methods for full, 1-compartment, and single-sample renal clearance characterization are discussed. GFR normalization and the role of GFR measurement in chemotherapy dosing are also considered.

No abstract